Home > Insider Trading > Filing (0001104659-11-006466)

Filing Details

Accession Number:: 0001104659-11-006466
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-02-10 18:47:36
Reporting Period:: 2011-02-08

Filing Date:: 2011-02-10
Accepted Time:: 2011-02-10 18:47:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1282930	L Carl Gordon	C/O Orbimed Advisors Llc 767 Third Avenue, 30Th Floor New York NY 10017		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-02-08	1,473,645	$0.00	1,566,625	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	14,035	$0.00	1,580,660	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	705,845	$13.44	2,286,505	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	6,722	$13.44	2,293,227	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	265,331	$7.00	2,558,558	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	2,526	$7.00	2,561,084	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	265,330	$7.00	2,826,414	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2011-02-08	2,527	$7.00	2,828,941	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2011-02-08	1,473,645	$0.00	1,473,645	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2011-02-08	14,035	$0.00	14,035	$0.00
Common Stock	Convertible Promissory Notes	Disposition	2011-02-08	705,845	$0.00	705,845	$13.44
Common Stock	Convertible Promissory Notes	Disposition	2011-02-08	6,722	$0.00	6,722	$13.44

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Represents shares of Common Stock acquired upon the automatic conversion of Series A convertible preferred stock upon the closing of the Issuer's initial public offering of Common Stock.
The Series A convertible preferred stock did not have an expiration date. The Series A convertible preferred stock automatically converted into shares of Common Stock at an effective conversion ratio of one-to-one upon the closing of the Issuer's initial public offering of Common Stock.
The reporting person is affiliated with OrbiMed Private Investments III, LP ("OPI") and OrbiMed Associates III, LP ("Associates"), which hold the securities reported herein. OrbiMed Capital GP III LLC ("Capital") is the sole general partner of OPI. OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital and the sole general partner of Associates. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. OPI and Associates have designated a representative, currently the reporting person, a member of Advisors, to serve on the Issuer's board of directors.
The reporting person does not have sole voting or investment power over the securities held by OPI and Associates. However, the reporting person may be deemed to have beneficial ownership of these securities by virtue of his affiliation with Advisors. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
These securities are beneficially owned by OPI.
These securities are beneficially owned by Associates.
Represents shares of Common Stock acquired upon the automatic conversion of all principal and accrued interest due on convertible promissory notes upon the closing of the Issuer's initial public offering of Common Stock at an effective conversion price of approximately $13.44.
These shares of Common Stock were acquired upon the conversion of convertible promissory notes exempt from the definition of a derivative security because the conversion price of such securities did not become fixed until their automatic conversion at the time of the closing of the Issuer's initial public offering of Common Stock.
Represents shares of Common Stock acquired upon the conversion of convertible promissory notes issued in December 2010. The outstanding principal amount and accrued but unpaid interest therein was automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock at an effective conversion price of $7.00, which represents the initial public offering price per share of the Common Stock sold by the Issuer.
These derivative securities are no longer beneficially owned.